<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Patents</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors</title>
      <description>
        <![CDATA[Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors potentially useful for the treatment of cancer, pain, fibrosis and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731753</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731753-empire-discovery-institute-univ-of-rochester-identify-irak-inhibitors</link>
    </item>
    <item>
      <title>Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors</title>
      <description>
        <![CDATA[Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731752</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731752-antares-therapeutics-divulges-new-cdk2-cyclin-e1-inhibitors</link>
    </item>
    <item>
      <title>Eikon Therapeutics discloses new USP1 inhibitors</title>
      <description>
        <![CDATA[Eikon Therapeutics Inc. has disclosed new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731751</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731751-eikon-therapeutics-discloses-new-usp1-inhibitors</link>
    </item>
    <item>
      <title>U.S. researchers report new antimalarial compounds</title>
      <description>
        <![CDATA[Brown University, Florida Atlantic University and Florida International University have jointly identified new compounds potentially useful for the treatment of malaria.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731750</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731750-us-researchers-report-new-antimalarial-compounds</link>
    </item>
    <item>
      <title>Onkure Therapeutics patents new PI3Kα mutant inhibitors</title>
      <description>
        <![CDATA[Onkure Therapeutics Inc. has disclosed new benzopyridinones acting as phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA-related overgrowth spectrum (PROS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731749</guid>
      <pubDate>Mon, 08 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731749-onkure-therapeutics-patents-new-pi3k-mutant-inhibitors</link>
    </item>
    <item>
      <title>Simcere Zaiming Pharmaceutical discovers new MAPK inhibitors</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd. has divulged new mitogen-activated protein kinase (MAPK) inhibitors found to be potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731687</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731687-simcere-zaiming-pharmaceutical-discovers-new-mapk-inhibitors</link>
    </item>
    <item>
      <title>Avelos Therapeutics synthesizes new PARG inhibitors</title>
      <description>
        <![CDATA[Avelos Therapeutics Inc. has identified new poly(ADP-ribose) glycohydrolase (PARG) inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731686</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731686-avelos-therapeutics-synthesizes-new-parg-inhibitors</link>
    </item>
    <item>
      <title>New York University identifies new analogues of mannose-6-phosphate</title>
      <description>
        <![CDATA[New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment, neurodegeneration and neurodevelopmental disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731685</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731685-new-york-university-identifies-new-analogues-of-mannose-6-phosphate</link>
    </item>
    <item>
      <title>Hengrui Pharmaceutical divulges new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have reported molecular glue degraders acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731684</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731684-hengrui-pharmaceutical-divulges-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech patents new anthracyclins</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed new anthracyclins that are useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731683</guid>
      <pubDate>Fri, 05 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731683-sichuan-kelun-biotech-patents-new-anthracyclins</link>
    </item>
    <item>
      <title>SCOTUS breathes new life into skinny labels</title>
      <description>
        <![CDATA[The U.S. Supreme Court handed Hikma Pharmaceuticals and the entire generic industry a big victory June 4 with its 9-0 opinion ensuring the future of skinny labels and correcting the Federal Circuit’s flawed understanding of infringed inducement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731619</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731619-scotus-breathes-new-life-into-skinny-labels</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Generic-drugs.webp?t=1588352361" type="image/png" medium="image" fileSize="183798">
        <media:title type="plain">Generic drugs and bottle</media:title>
      </media:content>
    </item>
    <item>
      <title>Dual PPARδ/α agonists reported in Shenzhen Hightide Biotechnology patent</title>
      <description>
        <![CDATA[Shenzhen Hightide Biopharmaceutical Ltd. has identified new peroxisome proliferator-activated receptor δ (PPARδ) and PPARα dual agonists potentially useful for the treatment of obesity, aging, cardiovascular disorders, heart failure, inflammatory disorders, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), metabolic syndrome and renal failure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731667</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731667-dual-ppar-agonists-reported-in-shenzhen-hightide-biotechnology-patent</link>
    </item>
    <item>
      <title>Pfizer patents new PI3Kα mutant inhibitors</title>
      <description>
        <![CDATA[Pfizer Inc. has reported new biaryl acid compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731666</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731666-pfizer-patents-new-pi3k-mutant-inhibitors</link>
    </item>
    <item>
      <title>Bial-Portela discovers new OX1 receptor antagonists</title>
      <description>
        <![CDATA[Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders, schizophrenia, obesity, sleep disorders, post-traumatic stress, substance abuse and dependence, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731665</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731665-bial-portela-discovers-new-ox1-receptor-antagonists</link>
    </item>
    <item>
      <title>Assembly Biosciences synthesizes new anti-cytomegalovirus agents</title>
      <description>
        <![CDATA[Assembly Biosciences Inc. has divulged new dihydroquinazolines potentially useful for the treatment of cytomegalovirus (CMV) infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731664</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731664-assembly-biosciences-synthesizes-new-anti-cytomegalovirus-agents</link>
    </item>
    <item>
      <title>Incyte discloses new GTPase KRAS inhibitors</title>
      <description>
        <![CDATA[Incyte Corp. has synthesized new GTPase KRAS inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731663</guid>
      <pubDate>Thu, 04 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731663-incyte-discloses-new-gtpase-kras-inhibitors</link>
    </item>
    <item>
      <title>Changchun Genescience identifies new USP30 inhibitors</title>
      <description>
        <![CDATA[Changchun Genescience Pharmaceuticals Co. Ltd. has discovered new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors potentially useful for the treatment of mitochondrial and Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731609</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731609-changchun-genescience-identifies-new-usp30-inhibitors</link>
    </item>
    <item>
      <title>Sichuan Kelun-Biotech prepares GSPT1-degrading PROTACs</title>
      <description>
        <![CDATA[Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has reported new proteolysis targeting chimera (PROTACs) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731608</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731608-sichuan-kelun-biotech-prepares-gspt1-degrading-protacs</link>
    </item>
    <item>
      <title>FAPα inhibitors disclosed in Chomix Biotech patent</title>
      <description>
        <![CDATA[Chomix Biotech (Nanjing) Co. Ltd. has patented new irreversible fibroblast activation protein-α (FAPα) inhibitors potentially useful for the diagnosis or treatment of rheumatoid arthritis, atherosclerosis, cancer, myocardial infarction, kidney fibrosis, pulmonary and hepatic fibrosis, and among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731607</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731607-fap-inhibitors-disclosed-in-chomix-biotech-patent</link>
    </item>
    <item>
      <title>Synnovation Therapeutics reports new PARG inhibitors</title>
      <description>
        <![CDATA[Synnovation Therapeutics Inc. has identified new heterocyclic poly(ADP-ribose) glycohydrolase (PARG) inhibitors described as useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731606</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731606-synnovation-therapeutics-reports-new-parg-inhibitors</link>
    </item>
    <item>
      <title>BMS patents new CAMK2 inhibitors</title>
      <description>
        <![CDATA[Bristol Myers Squibb Co. (BMS) has disclosed new 1H-benzo[d]imidazole derivatives acting as calcium/calmodulin-dependent protein kinase type II (CAMK2) inhibitors potentially useful for the treatment of anxiety disorders, asthma, cardiomyopathy, diabetes, fibrosis, heart failure, hypertension and allergy, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731605</guid>
      <pubDate>Wed, 03 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731605-bms-patents-new-camk2-inhibitors</link>
    </item>
    <item>
      <title>Wigen Biomedicine Technology patents new GTPase KRAS inhibitors</title>
      <description>
        <![CDATA[Wigen Biomedicine Technology (Shanghai) Co. Ltd. has discovered new GTPase KRAS inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731591</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731591-wigen-biomedicine-technology-patents-new-gtpase-kras-inhibitors</link>
    </item>
    <item>
      <title>China Pharmaceutical University discloses new asiaticoside saponin compounds</title>
      <description>
        <![CDATA[China Pharmaceutical University and the Chongqing Innovation Institute, China Pharmaceutical University have synthesized new asiaticoside saponin compounds reported to be useful for the treatment of inflammation, cancer and ulcerative colitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731590</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731590-china-pharmaceutical-university-discloses-new-asiaticoside-saponin-compounds</link>
    </item>
    <item>
      <title>Blossomhill Therapeutics discovers new EGFR mutant inhibitors</title>
      <description>
        <![CDATA[Blossomhill Therapeutics Inc. has patented new EGFR (HER1; erbB1) mutant inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731589</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731589-blossomhill-therapeutics-discovers-new-egfr-mutant-inhibitors</link>
    </item>
    <item>
      <title>Janssen Pharmaceutica reports new TMEM175 activators</title>
      <description>
        <![CDATA[Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731588</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731588-janssen-pharmaceutica-reports-new-tmem175-activators</link>
    </item>
    <item>
      <title>Cytosinlab Therapeutics identifies new HDAC1 inhibitors</title>
      <description>
        <![CDATA[Cytosinlab Therapeutics Co. Ltd. has discovered new histone deacetylase 1 (HDAC1) inhibitors reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731587</guid>
      <pubDate>Tue, 02 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731587-cytosinlab-therapeutics-identifies-new-hdac1-inhibitors</link>
    </item>
    <item>
      <title>Army Medical University reports new cGAS/STING pathway inhibitors</title>
      <description>
        <![CDATA[Army Medical University has identified new cyclic GMP-AMP synthase (MB21D1; cGAS)/STING pathway inhibitors potentially useful for the treatment of inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731570</guid>
      <pubDate>Mon, 01 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731570-army-medical-university-reports-new-cgas-sting-pathway-inhibitors</link>
    </item>
    <item>
      <title>Muna Therapeutics discloses TREM2 agonists</title>
      <description>
        <![CDATA[Muna Therapeutics Aps has patented new dihydropyrrolopyrimidinone compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), neurodegeneration and inflammatory bowel disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731569</guid>
      <pubDate>Mon, 01 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731569-muna-therapeutics-discloses-trem2-agonists</link>
    </item>
    <item>
      <title>HIV integrase inhibitors divulged in MSD patent</title>
      <description>
        <![CDATA[Merck Sharp & Dohme LLC (MSD) has reported new HIV integrase inhibitors potentially useful for the treatment of HIV infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731568</guid>
      <pubDate>Mon, 01 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731568-hiv-integrase-inhibitors-divulged-in-msd-patent</link>
    </item>
    <item>
      <title>Deep Apple Therapeutics synthesizes GIPR antagonists</title>
      <description>
        <![CDATA[Deep Apple Therapeutics Inc. has divulged new alkylphenyl substituted compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of obesity and type 2 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731567</guid>
      <pubDate>Mon, 01 Jun 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731567-deep-apple-therapeutics-synthesizes-gipr-antagonists</link>
    </item>
  </channel>
</rss>
